![Markus Goebel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Markus Goebel
Directeur/Membre du Conseil chez
OSE IMMUNOTHERAPEUTICS
Profil
Markus Goebel has held various director positions in multiple pharmaceutical and biotech companies.
He is currently a Director at FoldRx.
Pharmaceuticals LLC, Sorbent Therapeutics, Inc., EraGen Biosciences, Inc., Merganser Biotech, Inc., and OSE Immunotherapeutics SA. In the past, he has also served as a Director at Sirtris Pharmaceuticals, Inc., Ra Pharmaceuticals, Inc., Zikani Therapeutics, Inc., Locus Pharmaceuticals, Inc., LigoCyte Pharmaceuticals, Inc., Intellikine LLC, Novartis Services, Inc., Novartis Venture Funds (USA), eFFECTOR Therapeutics Operations, Inc., and ESCAPE Bio, Inc. Dr. Goebel holds an MBA from Henley Management College and a doctorate from Ludwig-Maximilians-Universität München.
Postes actifs de Markus Goebel
| Sociétés | Poste | Début |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Directeur/Membre du Conseil | 19/06/2024 |
Merganser Biotech, Inc.
 Merganser Biotech, Inc. BiotechnologyHealth Technology Provides biotechnology services | Directeur/Membre du Conseil | - |
FoldRx Pharmaceuticals LLC
 FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services | Directeur/Membre du Conseil | - |
EraGen Biosciences, Inc.
 EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets molecular diagnostic testing products | Directeur/Membre du Conseil | 01/01/2004 |
Sorbent Therapeutics, Inc.
 Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Markus Goebel
| Sociétés | Poste | Fin |
|---|---|---|
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Private Equity Investor | 30/04/2019 |
LigoCyte Pharmaceuticals, Inc.
 LigoCyte Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Developed vaccines and monoclonal antibody therapeutics | Directeur/Membre du Conseil | 16/04/2014 |
Locus Pharmaceuticals, Inc.
 Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services | Directeur/Membre du Conseil | - |
Novartis Services, Inc.
 Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company | President | 29/01/2010 |
| ░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Markus Goebel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
36
Relations au 1er degré
17
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 17 |
|---|---|
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Provides drug discovery and clinical development services | Health Technology |
Sirtris Pharmaceuticals, Inc.
 Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures drugs and pharmaceuticals | Health Technology |
Sorbent Therapeutics, Inc.
Sorbent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for cardiovascular and renal diseases | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Zikani Therapeutics, Inc.
 Zikani Therapeutics, Inc. Drugstore ChainsRetail Trade Focuses on the discovery and development of novel macrolide antibiotics for the treatment of life-threatening bacterial infections caused by drug resistant pathogens | Retail Trade |
Locus Pharmaceuticals, Inc.
Locus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Provides drug discovery and development services | Health Technology |
EraGen Biosciences, Inc.
EraGen Biosciences, Inc. Medical SpecialtiesHealth Technology Designs, develops, manufactures and markets molecular diagnostic testing products | Health Technology |
Henley Management College
 Henley Management College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
LigoCyte Pharmaceuticals, Inc.
LigoCyte Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Developed vaccines and monoclonal antibody therapeutics | Health Technology |
Intellikine LLC
 Intellikine LLC Pharmaceuticals: MajorHealth Technology Develops and manufactures small molecule drugs for the treatment of cancer | Health Technology |
Novartis Services, Inc.
Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company | Health Technology |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
eFFECTOR Therapeutics Operations, Inc.
 eFFECTOR Therapeutics Operations, Inc. BiotechnologyHealth Technology Operates a clinical-stage biopharmaceutical company that develops oncology drugs | Health Technology |
Merganser Biotech, Inc.
Merganser Biotech, Inc. BiotechnologyHealth Technology Provides biotechnology services | Health Technology |
OSE Immunotherapeutics SA
 OSE Immunotherapeutics SA Pharmaceuticals: MajorHealth Technology Develops immunotherapy products for late-stage cancers | Health Technology |
ESCAPE Bio, Inc.
 ESCAPE Bio, Inc. BiotechnologyHealth Technology Develops small molecule therapeutics against genetic targets for neurodegenerative disease | Health Technology |
